CJC-1295 (No DAC) vs GHRP-2
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Also: Growth Hormone Releasing Peptide 2, Pralmorelin
A synthetic hexapeptide that potently stimulates GH release. More potent than GHRP-6 with less appetite stimulation, but still elevates cortisol and prolactin.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- These GH secretagogues are frequently combined to enhance growth hormone release.
Detailed Comparison
| Attribute | CJC-1295 (No DAC) | GHRP-2 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes. | GHRP-2 acts on ghrelin receptors to stimulate GH release from the pituitary. It has the strongest GH-releasing effect among GHRPs but also causes more cortisol and prolactin release than ipamorelin. Less appetite stimulation than GHRP-6. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | 100-300 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks | 8-12 weeks |
| Best Time to Take | Before bed | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg. | Studies show it produces the highest GH release among common GHRPs. Research demonstrates reliable diagnostic use for GH deficiency testing. Animal studies show improved muscle mass and recovery. |
Frequently Asked Questions: CJC-1295 (No DAC) vs GHRP-2
What is the difference between CJC-1295 (No DAC) and GHRP-2?
CJC-1295 (No DAC) is a growth hormone peptide that a synthetic analog of growth hormone-releasing hormone (ghrh) that stimulates gh release from the pituitary. often combined with a ghrp like ipamorelin for synergistic effects. GHRP-2 is a growth hormone peptide that a synthetic hexapeptide that potently stimulates gh release. more potent than ghrp-6 with less appetite stimulation, but still elevates cortisol and prolactin. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 (No DAC) or GHRP-2?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 (No DAC) is typically used for growth hormone purposes, while GHRP-2 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 (No DAC) and GHRP-2 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 (No DAC) and GHRP-2 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.